Supernus (SUPN) Stock Price Target 2026

The average analyst price target for Supernus is $60.17, 117.8% above the current price. Of 5 analysts, 4 rate it Buy and 1 Hold. Targets range from $47 to $87. The latest change came on Nov 9, 2026, when B of A Securities initiated coverage of Supernus with a Buy rating and a $47 price target.

The Average Analyst Price Target for Supernus is $60.17.

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$60.17Upside to Avg. PT+117.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Supernus Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 9, 2026	B of A Securities	Chi Fong	Initiate	Buy	$47
Nov 4, 2026	Piper Sandler	David Amsellem	Reinstates	Overweight	$47
Nov 4, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$67→$87
Jul 9, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$63→$67
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Hold	$50→$55
Oct 29, 2025	B of A Securities	Pavan Patel	Initiate	Buy	$65
Oct 23, 2025	TD Cowen	Stacy Ku	PT Raise	Buy	$45→$60
Oct 9, 2025	Piper Sandler	David Amsellem	Upgrade	Neutral→Overweight	$40→$65
Sep 30, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$46→$63
Aug 29, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$36→$40
Aug 6, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$42→$46
Feb 26, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Neutral	$36
Feb 19, 2025	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	$57→$36
Sep 11, 2024	Piper Sandler	David Amsellem	Downgrade	Overweight→Neutral	$41→$36
Feb 28, 2024	Piper Sandler	David Amsellem	PT Cut	Overweight	$45→$41

Analyst Ratings News

This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47

B of A Securities analyst Chi Fong initiates coverage on Supernus (NASDAQ:SUPN) with a Buy rating and announces Price Target of $47.

Benzinga Newsdesk

PRO
Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target

Piper Sandler analyst David Amsellem reinstates Supernus (NASDAQ:SUPN) with a Overweight and announces $47 price target.

Benzinga Newsdesk

Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.

Avi Kapoor

PRO
Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus (NASDAQ:SUPN) with a Overweight and raises the price target from $67 to $87.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.

Benzinga Newsdesk

Supernus Inc

Supernus (SUPN) Stock Price Target 2026

The Average Analyst Price Target for Supernus is $60.17.

Latest Upgrades and Downgrades for Supernus Stock

Analyst Ratings News

This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROB of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47

PROPiper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target

Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday

PROCantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87

PROCantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PRO
B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47

PRO
Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67